疏肝解郁胶囊与米氮平治疗复发性抑郁障碍对照研究

A control study of Shugan Jieyu capsule vs. mirtazapine in the treatment of recurrent depressive disorder

目的探讨疏肝解郁胶囊与米氮平治疗复发性抑郁障碍患者的临床疗效以及对认知功能的影响。方法将120例复发性抑郁障碍患者采用随机数字表法分为观察组和对照组，每组60例，分别口服疏肝解郁胶囊和米氮平治疗，观察16周。于治疗前后采用汉密顿抑郁量表评定临床疗效，采用威斯康星卡片分类测验、Stroop字色测验、中国修订韦氏成人智力量表评定认知功能。结果治疗后两组汉密顿抑郁量表总分及各因子评分均较治疗前显著下降（P〈0．05或0．01），Stroop字色测验及韦氏成人智力量表评分与治疗前比较差异均有显著性（P〈0．05或0．01），同期两组间各量表测评结果比较差异均无显著性（P〉0．05）。治疗16周末观察组有效率为88．3％，对照组为85．0％，两组比较差异无显著性（P〉0．05）。结论疏肝解郁胶囊与米氮平治疗复发性抑郁障碍疗效显著且相当，均能有效改善患者的认知功能。

Objective To explore the efficacy of Shugan Jieyu capsule vs. mirtazapine in the treatment of recurrent depressive disorder and influence on codnitive function. Methods A total of 120 patients with recurrent depressive disorder were randomly divided into observation and control group of 60 ones each taking orally Shugan Jieyu capsule or mirtazapine for 16 weeks. Efficacies were assessed with Hamilton Depression Scale （HAMD） before and after treatment and cognitive functions with Wisconsin Card Sorting Test （WCST）, Stroop Color-Word Association Test （SCWAT） and Chinese revision of the Wechsler Adult Intelligence Scale （WAIS-RC）. Results After treatment the total and each factor scores of the HAMD of both groups significantly continuously lowered compared with pretreatment （P〈0.05 or 0.01）, there were significant differences between post- and pre-treatment SCWAT and WAIS-RC scores （P〈0.05 or 0.01）, and no significant group differences in all scales scores （P〉0.05）. At the end of the 16^t＇h week effective rate was respectively 88.3 % in observation and 85.0 % in control group, which showed no significant group difference （P〉0.05）. Conclusion Mirtazapine and Shugan Jieyu capsule are similarly effective in the treatment of recurrent depressive disorder and could effectively improve patients cognitive function.